Colorado-based biotech startup Enveda has raised $311 million in a Series E funding round led by Catalio Capital Management, doubling its valuation to $2 billion. Enveda utilizes an AI platform to identify and rank therapeutic compounds from plants and microbes. The startup plans to use the capital to fund later-stage clinical trials, including candidates for severe skin conditions and weight loss maintenance after GLP-1 cessation, amid growing momentum for tech-driven drug discovery.
Series E Funding and Valuation
- ▪Enveda raised $311 million in a Series E funding round, valuing the biotechnology startup at approximately $2 billion
- ▪Enveda's $311 million Series E funding round was led by Catalio Capital Management, with participation from Iconiq and other investors, including backing from former Johnson & Johnson Chief Executive Alex Gorsky
- ▪The $2 billion valuation achieved by Enveda doubles the valuation the startup had 12 months prior
Clinical Trial Pipeline
- ▪Enveda is currently testing several drug candidates in patients, including one targeting severe skin conditions and another designed to maintain weight loss after stopping GLP-1 medications
- ▪Enveda plans to use the $311 million Series E funding to advance its drug candidates into later-stage human clinical trials
AI-Driven Drug Discovery
- ▪Enveda's valuation increase to $2 billion comes amid growing momentum behind technology-driven approaches to discovering new medicines
- ▪While artificial intelligence has not yet produced any FDA-approved drugs, Enveda is part of a wave of companies advancing AI-discovered drug candidates into human clinical trials
- ▪Enveda uses an artificial intelligence platform to identify, rank, and harness therapeutic drug compounds from plants and microbes rather than synthesizing them from scratch
Story comments
Loading comments…